Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy

Table 4 Comparison of profile between sustained virological response and non-sustained virological response patients

Factors	SVR (n = 54)	non-SVR (n = 66)	P value
Age (yr)	57 ± 12	61 ± 9	< 0.05
Gender: male/female	21/33	33/33	NS
Body mass index (kg/m2)	23.5 ± 4.1	22.6 ± 3.3	NS
HCV RNA (log IU/mL)	5.9 ± 0.6	6.1 ± 0.6	< 0.05
Hemoglobin (g/dL)	13.7 ± 1.3	13.8 ± 1.8	NS
WBC (× 103/mL)	4.7 ± 1.3	5.1 ± 1.5	NS
Platelet (× 104/mL)	20 ± 7	17 ± 6	< 0.05
AST (IU/L)	46.2 ± 25.8	66.7 ± 47.1	NS
ALT (IU/L)	56.1 ± 33.3	75.1 ± 61.1	NS
GGT (IU/L)	39.8 ± 24.1	67.4 ± 61.2	NS
AFP (ng/mL)	8.3 ± 19.8	10.1 ± 24.2	NS
Staging: F1,2/F3,4	12/40	28/30	< 0.01
72 wk treatment: +/–	10/44	14/52	NS
Ribavirin dose (%)1	90 ± 35	76 ± 41	NS
ITPA: CC/CA + AA	38/16	45/21	NS
IL28B: TT/TG + GG	44/10	38/28	< 0.01

¹Percentage of ribavirin administration to the scheduled total dose of full-length treatment (48 or 72 wk). SVR: Sustained virological response; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein; ITPA: inosine triphosphatase; NS: Not significant; HCV: Hepatitis C virus; IL28B: Interleukin 28B.